Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Allogeneic Cell Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CIITA drug discovery and gene-editing validation. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CIITA Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for interaction assays. |
View CIITA Products |
| Gene Delivery | CIITA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and MHC II induction studies. |
View CIITA Products |
| Benchmark Ab | Anti-CIITA Recombinant Antibody High-specificity positive control for Western Blot, ChIP, and intracellular flow cytometry. |
View CIITA Products |
| Validator | CIITA siRNA Set For target knockdown verification and functional rescue assays. |
View CIITA Products |
| Related Target A | B2M Co-target with CIITA in allogeneic CAR-T/NK cell therapies to eliminate HLA Class I and II expression for hypoimmunogenicity. |
View B2M Products |
| Related Target B | NLRC5 MHC Class I transactivator, working in tandem with CIITA to regulate global antigen presentation pathways. |
View NLRC5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Validation of CIITA Gene Knockout in Universal CAR-T | Sequence-verified Lentivirus and high-specificity antibodies for genomic and protein-level KO validation. |
| Intracellular Protein Interaction Screening (e.g., RFX complex) | High-purity recombinant CIITA proteins with native fold and theoretical molecular weight verification. |
| Lack of Controls | Clinical-grade benchmark validation antibodies included |
| False Positives | Validated siRNA sets included for specificity checks in RNAi assays |
Live CIITA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CIITA-related therapeutics is intensifying, with major players shifting focus from traditional oncology targets to allogeneic cell therapy engineering. As first-generation autologous therapies face scalability bottlenecks, the next wave of R&D is targeting CIITA gene knockout to create "off-the-shelf" hypoimmunogenic CAR-T and CAR-NK platforms.
By disrupting the CIITA gene, researchers can selectively silence MHC Class II expression, preventing host CD4+ T-cell-mediated rejection of donor cells. Conversely, in oncology, small molecules aimed at restoring CIITA function are being explored to reverse tumor immune evasion caused by MHC Class II downregulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allogeneic Cell Therapy (Gene Editing) | CRISPR Therapeutics, Allogene Therapeutics, Sana Biotechnology | B-cell Malignancies, Solid Tumors | MHC Class II Knockout Validation (Need CIITA Lentivirus & siRNA) |
| Small Molecule / Transcription Inhibitors | Academic Consortia, Biotech Startups | Autoimmune Diseases, Graft-versus-Host Disease (GvHD) | In vitro Transcription & Binding Assays (Need High-Purity Recombinant Protein) |
| Gene Therapy / Vector Delivery | Sana Biotechnology (Fusogen platform) | In vivo CAR-T, Genetic Disorders | In vivo Expression Verification (Need Sequence-Verified ORF Lentivirus) |